Dr. Pant on the Future of mCRC Treatment

Shubham Pant, MD
Published: Wednesday, Mar 28, 2018



Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

The future looks very promising. Pant notes that years ago, lung cancer was divided into non–small cell lung cancer, adenocarcinoma, squamous cell carcinoma, etc. Now, diagnoses are becoming more specific to EGFR, ALK, ROS1, and other abnormalities.

The hope is to be able to stratify CRCs the same way. Right now, there are microsatellite instability-high, and BRAF-mutated cancers. Additionally, patients with KRAS mutations need new therapies. KRAS inhibitors are in development. Combination approaches with translocations downstream of KRAS, such as RAS, RAF, MEK, ERK may be worth investigating.
 
SELECTED
LANGUAGE


Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

The future looks very promising. Pant notes that years ago, lung cancer was divided into non–small cell lung cancer, adenocarcinoma, squamous cell carcinoma, etc. Now, diagnoses are becoming more specific to EGFR, ALK, ROS1, and other abnormalities.

The hope is to be able to stratify CRCs the same way. Right now, there are microsatellite instability-high, and BRAF-mutated cancers. Additionally, patients with KRAS mutations need new therapies. KRAS inhibitors are in development. Combination approaches with translocations downstream of KRAS, such as RAS, RAF, MEK, ERK may be worth investigating.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Publication Bottom Border
Border Publication
x